Fig. 1
From: Inhibiting CXCR4 reduces immunosuppressive effects of myeloid cells in breast cancer immunotherapy
Balixafortide functions as an inverse agonist for CXCR4. We measured levels of (A) AKT and C) ERK using kinase translocation reporters (KTRs) in MDA-MB-231 breast cancer cells after treatment with different CXCR4 antagonists as indicated. Bars show mean + SEM values for kinase activity after 30 min of treatment with the listed compounds. Data represent the log2 of cytoplasmic/nuclear fluorescence intensities for each reporter (n > 400 cells per condition). We quantified activation of (B) AKT and D) ERK by KTRs after treatment with 100 ng/ml CXCL12-α added at time 0 (arrow). Data represent mean values for log2 of cytoplasmic/nuclear fluorescence intensities at each time point. We tracked > 300 cells over time for each condition. Error bars denote SEM where visible beyond the symbol. Data for all panels are representative of two independent experiments. *, p < 0.05, **, p < 0.01.
